Maria Nachury

Maria Nachury

Auto-generated profile, based on publicly available information

Maria Nachury

Hepato-Gastroenterology Department, Claude Huriez hospital, University of Lille 2, Lille, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in The Lancet
Verified
Journal Article
Closed access
JPJulián Panés
Julián Panés
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
GAGert Van Assche
Gert Van Assche
JCJean Frederic Colombel
Jean Frederic Colombel
WRWalter Reinisch
Walter Reinisch
SDSilvio Danese
Silvio Danese

1 December 2012 in The Lancet
Verified
Journal Article
Closed access
DLDavid Laharie
David Laharie
ABArnaud Bourreille
Arnaud Bourreille
JBJulien Branche
Julien Branche
MAMatthieu Allez
Matthieu Allez
YBYoram Bouhnik
Yoram Bouhnik
MLMarc Lémann
Marc Lémann

1 April 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JPJulián Panés
Julián Panés
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
GAGert Van Assche
Gert Van Assche
JCJean Frederic Colombel
Jean Frederic Colombel
WRWalter Reinisch
Walter Reinisch
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara

1 November 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDPierre Desreumaux
Pierre Desreumaux
AFArnaud Foussat
Arnaud Foussat
MAMatthieu Allez
Matthieu Allez
LBLaurent Beaugerie
Laurent Beaugerie
XHXavier Hébuterne
Xavier Hébuterne
JCJean–Frédéric Colombel
Jean–Frédéric Colombel

18 January 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
LML. Marthey
L. Marthey
CMC. Mateus
C. Mateus
CMC. Mussini
C. Mussini
MNM. Nachury
M. Nachury
SNStephane NANCEY
Stephane NANCEY
FCF. Carbonnel
F. Carbonnel
Background: Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity. Methods: We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated melanoma were compared, to identify clinical factors associated with enterocolitis. Results: Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab n = 37; tremelimumab n = 2). The most frequent symptom was diarrhoea. Ten patients had extra-intestinal manifestations. Most colonoscopies showed ulcerations involving the rectum and sigmoid, 66% of patients had extensive colitis, 55% had patchy distribution and 20% had ileal inflammation. Endoscopic colonic biopsies showed acute colitis in most patients, while half of the patients had chronic duodenitis. Thirty-five patients received steroids that led to complete clinical remission in 13 patients (37%). Twelve patients required infliximab, of whom 10 (83%) responded. Six patients underwent colectomy (perforation n = 5; toxic megacolon n = 1); one of them died postoperatively. Four patients had a persistent enterocolitis at follow-up colonoscopy. Patients with enterocolitis were more frequently prescribed NSAIDs compared with patients without enterocolitis (31 vs 5%, p = 0.003). Conclusions: Ipilimumab and tremelimumab may induce a severe and extensive form of inflammatory bowel disease. Rapid escalation to infliximab should be advocated in patients who do not respond to steroids. Patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.

24 January 2017 in Gut
Verified
Journal Article
Open access
PDF file
YBYoram Bouhnik
Yoram Bouhnik
FCFranck Carbonnel
Franck Carbonnel
DLDavid Laharie
David Laharie
CSCarmen Stefanescu
Carmen Stefanescu
XHXavier Hébuterne
Xavier Hébuterne
JMJean-Yves Mary
Jean-Yves Mary
Objective The efficacy of anti-tumour necrosis factors (anti-TNFs) in patients with Crohn's disease (CD) and symptomatic small bowel stricture (SSBS) is controversial. The aim of this study was to estimate the efficacy of adalimumab in these patients and to identify the factors predicting success. Design We performed a multicentre, prospective, observational cohort study in patients with CD and SSBS. The included patients underwent magnetic resonance enterography at baseline and subsequently received adalimumab. The primary endpoint was success at week 24, defined as adalimumab continuation without prohibited treatment (corticosteroids after the eight week following inclusion, other anti-TNFs), endoscopic dilation or bowel resection. The baseline factors independently associated with success were identified using a logistic regression model, leading to a simple prognostic score. Secondary endpoints were prolonged success after week 24 (still on adalimumab, without dilation nor surgery) and time to bowel resection in the whole cohort. Results From January 2010 to December 2011, 105 patients were screened and 97 were included. At week 24, 62/97 (64%) patients had achieved success. The prognostic score defined a good prognosis group with 43/49 successes, an intermediate prognosis group with 17/28 successes and a poor prognosis group with 1/16 successes. After a median follow-up time of 3.8 years, 45.7%±6.6% (proportion±SE) of patients who were in success at week 24 (ie, 29% of the whole cohort) were still in prolonged success at 4 years. Among the whole cohort, 50.7%±5.3% of patients did not undergo bowel resection 4 years after inclusion. Conclusions A successful response to adalimumab was observed in about two-thirds of CD patients with SSBS and was prolonged in nearly half of them till the end of follow-up. More than half of the patients were free of surgery 4 years after treatment initiation. Clinical Trial registration number NCT01183403; Results.